

Resource Summary Report

Generated by RRID on Aug 5, 2026

Genomic Data Commons Data Portal (GDC Data Portal)

RRID:SCR_014514

Type: Tool

Proper Citation

Genomic Data Commons Data Portal (GDC Data Portal) (RRID:SCR_014514)

Resource Information

URL: <https://portal.gdc.cancer.gov/>

Proper Citation: Genomic Data Commons Data Portal (GDC Data Portal) (RRID:SCR_014514)

Description: A unified data repository of the National Cancer Institute (NCI)'s Genomic Data Commons (GDC) that enables data sharing across cancer genomic studies in support of precision medicine. The GDC supports several cancer genome programs at the NCI Center for Cancer Genomics (CCG), including The Cancer Genome Atlas (TCGA), Therapeutically Applicable Research to Generate Effective Treatments (TARGET), and the Cancer Genome Characterization Initiative (CGCI). The GDC Data Portal provides a platform for efficiently querying and downloading high quality and complete data. The GDC also provides a GDC Data Transfer Tool and a GDC API for programmatic access.

Synonyms: Genomic Data Commons Data Portal, GDC Data Portal

Resource Type: database, data or information resource

Keywords: genomics, data repository, portal, cancer, data sharing, cancer genomic studies

Related Condition: Cancer

Availability: Public, Available to the research community

Resource Name: Genomic Data Commons Data Portal (GDC Data Portal)

Resource ID: SCR_014514

Alternate IDs: r3d100012061

Old URLs: <https://gdc-portal.nci.nih.gov>

Record Creation Time: 20220129T080320+0000

Record Last Update: 20260805T044327+0000

Ratings and Alerts

No rating or validation information has been found for Genomic Data Commons Data Portal (GDC Data Portal).

No alerts have been found for Genomic Data Commons Data Portal (GDC Data Portal).

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 9880 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Dela Cruz FS, et al. (2026) Advancing Preclinical Biology for Ewing Sarcoma: An International Effort. Molecular cancer therapeutics, 25(1), 48.

Chen J, et al. (2026) Tumor Electric Field Therapy Inhibits TGF- β /C1R Signaling Axis-Driven Epithelial-Mesenchymal Transition in Glioblastoma. CNS neuroscience & therapeutics, 32(1), e70738.

Wang Q, et al. (2026) ACTG1 promotes breast cancer aggressiveness and confers ribociclib resistance by deubiquitinating HSPA8 through UCHL3. Cellular oncology (Dordrecht, Netherlands), 49(1), 14.

Su J, et al. (2026) TAF1 acetyltransferase promotes colorectal carcinoma metastasis by catalyzing γ -hydroxybutyrylation of KCTD9. Oncogene, 45(1), 87.

Song Y, et al. (2026) Evaluating and Optimizing Mass Spectrometry Proteomics Data to Deconvolve Cell-Type-Specific Protein Expression in Tumors. Journal of proteome research, 25(1), 471.

Cao H, et al. (2026) TDP2 drives immune evasion and metastatic progression in prostate cancer. PloS one, 21(1), e0339607.

Hu YM, et al. (2026) Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types. Cancer research communications, 6(1), 17.

Qian L, et al. (2026) Lysophosphatidic acid-induced Arf6-driven macropinocytosis of CD147+ extracellular vesicles promotes sorafenib resistance of hepatocellular carcinoma. International journal of biological sciences, 22(1), 220.

Tu Y, et al. (2026) DNMT inhibition epigenetically restores the cGAS-STING pathway and activates RIG-I/MDA5-MAVS to enhance antitumor immunity. *Acta pharmacologica Sinica*, 47(1), 197.

Machado L, et al. (2026) A unified model for Duchenne muscular dystrophy gene involvement in cancer: context-dependent tumour suppression and oncogenicity. *FEBS open bio*, 16(1), 222.

Li S, et al. (2026) Unveiling Alternative Splicing in HPV-Negative HNSCC: Links to Tumorigenesis and Immune Landscape. *International dental journal*, 76(1), 103857.

Angi E, et al. (2026) ACY-1215 and bortezomib cooperatively disrupt NOTCH3 signaling and induce anti-tumor effects in T-ALL models. *Biomarker research*, 14(1), 2.

Xie W, et al. (2026) CTHRC1 promotes the progression of clear cell renal cell carcinoma via the PI3K/AKT/GSK3 β signaling pathway. *Genes & diseases*, 13(2), 101688.

Tell R, et al. (2026) Lexicon for Clonal Hematopoiesis in Liquid Biopsy. *Clinical and translational science*, 19(1), e70463.

Liu Y, et al. (2026) A Novel MPT-Driven Necrosis-Related lncRNA Signature for Prognostic Prediction in Hepatocellular Carcinoma: Validation Using Organoids. *Cancer medicine*, 15(1), e71445.

Cen B, et al. (2026) The Role of RANBP3L in Pan-Cancer With Its Significance in Hepatocellular Carcinoma. *Cancer reports (Hoboken, N.J.)*, 9(1), e70440.

Pan R, et al. (2026) Basement membrane-associated gene P3H2 regulates osteosarcoma progression and epithelial-mesenchymal transition through AKT/mTOR signaling axis. *Translational oncology*, 63, 102569.

Feng H, et al. (2026) SV2B Promotes the Progression of TFE3-Rearranged Renal Cell Carcinoma by Interacting with HERC2 to Impede the Degradation of NF- κ B Subunits. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(1), e09443.

Xiong H, et al. (2026) Unveiling shared PANoptosis mechanisms in LUAD and osteoarthritis via bioinformatics and machine learning. *Translational oncology*, 63, 102586.

Meng Y, et al. (2026) c-Myc-regulated RPLP0 via the ROS-mediated JAK2/STAT3 positive feedback loop facilitates hepatocellular carcinoma malignancy progression. *International journal of oncology*, 68(1).